Advertisement


Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement



Jun
12
Today In Oncology
Immunotherapy With Cemiplimab-rwlc Yields Survival Benefit in Advanced Cervical Cancer
Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma
Are There Differences in the Prevalence of Germline Pathogenic Variants in Susceptibility Genes in Black vs White Women With Breast Cancer
Pembrolizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer KEYNOTE-057
Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside